JIANGZHONG PHARMACEUTICAL CO., LTD. – Trademark Portfolio
Entity Type: 99
JIANGZHONG PHARMACEUTICAL CO., LTD. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. The owner is based in Nanchang City, Jiangxi.
No.788 Huoju Avenue, Gaoxin Dev District
Nanchang City, Jiangxi 330096 , CN
Showing of trademarks Trademarks
Trademark Classifications
JIANGZHONG PHARMACEUTICAL CO., LTD.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does JIANGZHONG PHARMACEUTICAL CO., LTD. have?
JIANGZHONG PHARMACEUTICAL CO., LTD. has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending, 2 abandoned, 2 cancelled.
What trademark classes does JIANGZHONG PHARMACEUTICAL CO., LTD. file in?
JIANGZHONG PHARMACEUTICAL CO., LTD. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 29 (Meats & Processed Foods), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What is JIANGZHONG PHARMACEUTICAL CO., LTD.'s trademark registration success rate?
JIANGZHONG PHARMACEUTICAL CO., LTD. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 1 application is pending review.